Dublin, Dec. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Biologics CDMO Market - A Global and Regional Analysis, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The global biologics CDMO market is forecast to exceed $12 billion in 2023 and is anticipated to grow to over $25 billion by 2033, witnessing a CAGR of 7.62% during the forecast period 2023-2033.
The global biologics CDMO market plays a crucial role in the pharmaceutical and biotechnology industries, offering specialized services for the development, manufacturing, and testing of biologic drugs.
Biologics are complex molecules derived from living organisms, such as proteins, antibodies, and nucleic acids, and they have become increasingly important in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. CDMOs in the biologics sector provide a range of services, including cell line development, process development, scale-up, manufacturing, quality control, and regulatory support.
These organizations serve as strategic partners for pharmaceutical and biotech companies, allowing them to outsource certain aspects of the drug development and manufacturing process, thereby gaining efficiency, expertise, and flexibility.
How can this report add value to an organization?
Product/Innovation Strategy: The global biologics CDMO market has been extensively segmented based on various categories, such as cell type and product type. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Growth/Marketing Strategy: The global biologics CDMO market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint venture.
Competitive Strategy: Key players in the global biologics CDMO market analyzed and profiled in the study involve established and emerging players. Moreover, a detailed competitive benchmarking of the players operating in the global biologics CDMO market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.
Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Questions Answered in the Report:
- What is the estimated global biologics CDMO market size in terms of revenue for the forecast period 2023-2033, and what is the expected compound annual growth rate (CAGR) during the forecast period 2023-2033?
- What are the key market drivers and opportunities in the market pertaining to biologics CDMO?
- What are the major restraints inhibiting the growth of the global biologics CDMO market?
- What kinds of new strategies are being adopted by the existing market players to expand their market position in the industry?
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 165 |
| Forecast Period | 2023 - 2033 |
| Estimated Market Value (USD) in 2023 | $12 Billion |
| Forecasted Market Value (USD) by 2033 | $25 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
Markets: Industry Outlook
Trends: Current and Future Impact Assessment
- Emerging Gene and Cell Therapies
- Single-use Bioprocessing Equipment
- Trend Toward Personalized Medicine
Supply Chain Overview
- Value chain Analysis
- Market Map
- Cost of Manufacturing in CDMO/gm Forecast
Patent Analysis
- Awaited Technological Developments
- Patent Filing Trend by Country, by Year
- Patent Filing Trend by Country, by Country
Regulatory Landscape
Production Capacity
Factors Considered While Outsourcing To CDMO
Impact analysis for key global events- covid19, Russia/Ukraine or Middle East crisis
Market Dynamics Overview
- Market Drivers
- Market Restraints
- Market Opportunities
Competitive Landscape & Company Profiles
- Boehringer Ingelheim Group
- Lonza Group
- Samsung Biologics
- NOVARTIS AG
- Toyobo Co. Limited
- Parexel International Corporation
- Catalent Inc.
- Binex Co. Limited
- AGC Biologics
- AbbVie Contract Manufacturing
Market Segmentation
Cell Type
- Mammalian
- Non-mammalian
Product Type
- Biologics (Monoclonal Antibodies, Recombinant Proteins, Antisense and Molecular Therapy, Vaccines, Other Biologics)
- Biosimilars
Region
- North America
- Europe
- Asia-Pacific
- Latin America
- MEA
For more information about this report visit https://www.researchandmarkets.com/r/w85z3u
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
